ISRCTN70791258.

Study name	Treatment with adrenocorticotropic hormone in idiopathic membranous nephropathy
Methods	Study design: parallel, open‐label RCT Study duration: 6 July 1999 to 31 January 2005 Sample size: target 30
Participants	Setting: not reported Country: Sweden Inclusion criteria: males and females, aged 18 to 90 years; membranous nephropathy according to kidney biopsy; proteinuria of the nephrotic range for at least 6 months; treatment with a statin and an ACEi for at least 3 months; urinary albumin excretion > 3000 mg/24 hours; serum albumin concentration < 26 g/L Exclusion criteria: moderate or heavy tubulointerstitial changes in the kidney biopsy; recognisable cause of the nephrotic syndrome; previous immunosuppressive treatment for the membranous nephropathy; allergy to Synacthen Depot; severe psychiatric disease; pregnancy; history of noncompliance
Interventions	Group 1 Depot preparation of a synthetic fragment of ACTH versus no specific treatment. The dosage scheme of Synacthen Depot given subcutaneously was as follows: Month one: 1.0 mg once/week Month two: 0.75 mg twice/week Months three to six: 1.0 mg twice/week Month seven: 0.75 mg twice/week Month eight: 1.0 mg once/week Month nine: 0.5 mg once/week Control group Supportive therapy
Outcomes	Complete remission, at 9 and 21 months Complete and partial remission at the end of the treatment period (9 months after study start) and at the end of the follow‐up period (21 months after study start) Serum albumin SCr Apolipoprotein A1 Apolipoprotein B Lipoprotein(a) Urinary excretion/24 hours of albumin Immunoglobulin G Protein HC GFR Mean arterial pressure
Starting date
Contact information
Notes	Funding source: Department of Nephrology, University Hospital in Lund (Sweden) Information from trial registration site only (June 2018), emailed Ann‐lena.berg@njur.lu.se and sponsor kerstin.wihlborg@med.lu.se on 13 Jun 2018